Preliminary evaluation of the effect of WHO-MDT on disabilities in leprosy patients in Malaŵi (Central Africa).
D003622:Dapsone / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007918:Leprosy / Q000188:drug therapy* / Q000473:pathology; D008295:Malawi; D012293:Rifampin / Q000008:administration & dosage* / Q000627:therapeutic use
D003622:Dapsone; D012293:Rifampin